Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Patent Office Publishes Objection Filed Against BioPorto A/S' NGAL Trauma Patent

Tuesday, 25 Sep 2012 03:51am EDT 

BioPorto A/S announced that the European Patent Office (EPO) has published an objection filed against the granted NGAL trauma patent. Previously, in the report for the second quarter from August 23, 2012, the Company announced that its NGAL trauma patent is approved for issue by EPO. The Company also announced that oppositions to key patents in areas where other companies have an interest are not unusual. Oppositions are made with the purpose of limiting other companies' patent rights within the respective area. The Company has also added that as with previous objections to BioPorto's NGAL cutoff patent from several players within the NGAL field, the objection to the trauma patent is expected. The Company does not expect the opposition to the patent to result in changes in the obtained patent rights. An opposition may proceed in several years, but the patent rights remain unchanged during this process. The actual content of the oppositions and replies will be dealt with in cooperation with BioPorto's patent attorneys Hoiberg A/S and mentioned in BioPorto's reporting on IP rights. 

Company Quote

0.04 +1.65%
11 Jul 2014